Basilea Pharmaceutica Ltd. announced today that the European Medicines Agency (EMA) has accepted its isavuconazole Marketing Authorization Application (MAA) for review. Basilea's MAA seeks approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis (zygomycosis) in adults.

Ronald Scott, Basilea's CEO, stated: "We are very pleased with the EMA's acceptance of our MAA for review. This is an important milestone in the development of isavuconazole. Based on its profile, isavuconazole could potentially play an important role in the treatment of life-threatening invasive mold infections." He added: "Basilea is committed to bring new therapeutic options to patients with invasive infections."

For more details, go to: http://www.basilea.com/News-and-Media/European-Medicines-Agency-accepts-Basileas-isavuconazole-Marketing-Authorization-Application-for-review/261f60fb-2ee1-7218-fe95-fbc152ffcd4a